Why the study?
Developing broad coronavirus vaccines requires identifying and understanding the molecular basis of conserved spike epitopes targeted by broadly neutralizing antibodies.
Design
Structural and neutralization study
Key result
Group 1 and 2 broadly neutralizing antibodies retain neutralizing activity against highly mutated SARS-CoV-2 variants like BA.2.86 and JN.1 by targeting conserved spike receptor-binding domain epitopes.
Authors
Loading...
Animal data extend conserved RBD epitopes as vaccine targets; human efficacy remains unproven.
Identification of conserved spike RBD epitopes targeted by broadly neutralizing antibodies provides a potential target for broad coronavirus vaccines.
Song et al. (2025) studied SARS-CoV-2. Broadly neutralizing antibodies (group 1 and 2 bnAbs) was evaluated on Neutralizing activity against SARS-CoV-2 variants and structural interactions. Group 1 and 2 broadly neutralizing antibodies retain neutralizing activity against highly mutated SARS-CoV-2 variants like BA.2.86 and JN.1 by targeting conserved spike receptor-binding domain epitopes.